Filing Analysis
Delisting Notice
Filed Feb 27, 2026
HIGH
Jupiter Neurosciences received two deficiency notices from Nasdaq on February 26, 2026, for failing to maintain the $1.00 minimum bid price and the $35 million minimum market value of listed securities (MVLS). The company has 180 days, until August 25, 2026, to regain compliance with both requirements or face potential delisting.
Red Flags
- Dual non-compliance with Nasdaq listing standards (Bid Price and Market Value).
- Explicit mention of a potential reverse stock split to regain compliance.
- Market Value of Listed Securities has eroded below the $35 million requirement.
Key Facts
- Received Nasdaq notices on February 26, 2026, regarding Listing Rules 5550(a)(2) and 5550(b)(2).
- The closing bid price was below $1.00 for 30 consecutive business days from January 13, 2026, through February 25, 2026.
- The Market Value of Listed Securities (MVLS) closed below the $35 million threshold for 30 consecutive business days ended February 26, 2026.
- The company has until August 25, 2026, to regain compliance by maintaining the required thresholds for at least 10 consecutive business days.
- Management explicitly mentioned a reverse stock split as a potential option to resolve the bid price deficiency.
Material Agreement
Filed Feb 20, 2026
HIGH
Jupiter Neurosciences amended its convertible promissory notes and SEPA with Yorkville (YA II PN, LTD), extending the first monthly installment payment by approximately three months to April 1, 2026, and switching to a variable payment schedule. This modification to the existing $6.0 million convertible debt facility signals potential cash flow strain at this emerging growth biotech company.
Red Flags
- Yorkville (YA II PN) is a well-known provider of toxic convertible debt to micro-cap companies; their SEPA structures are inherently dilutive to existing shareholders
- Three-month payment extension strongly suggests the company lacks sufficient cash to meet original payment obligations — a liquidity warning sign
- Shift from fixed to variable payment schedule may allow Yorkville to accelerate conversions during stock price weakness, increasing dilution
- Convertible notes with $6.0M outstanding create significant overhang and dilution risk for common shareholders
- Multiple 8-K items (1.01 and 2.03) in a single filing compounds the significance
- Certain portions of exhibits redacted under Reg S-K 601(a)(6), limiting transparency on exact conversion and payment terms
- Company is an emerging growth biotech with no evident revenue — continued reliance on structured equity/debt financing
Key Facts
- Company amended convertible promissory notes originally issued under October 24, 2025 SEPA with Yorkville (YA II PN, LTD)
- Yorkville advanced up to $6.0 million to the company in two tranches via convertible promissory notes
- Omnibus Amendment dated February 20, 2026 extends first monthly installment payment to April 1, 2026 (~3 month extension)
- Payment calculation revised from prior terms to a variable payment schedule
- Company retains option to satisfy installments through cash, Advance Repayment, or combination thereof
- Advance Notice provisions under the SEPA were also updated
- Company is listed on Nasdaq Capital Market and is an emerging growth company
- Filed by CEO and Chairman Christer Rosén
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.